Septic shock is the leading cause of morbidity and mortality in intensive care units worldwide \[[@CR25]\]. It is accompanied by myocardial dysfunction in 40--44 % of adults and ≤80 % of children \[[@CR7], [@CR29]\]. Myocardial dysfunction is associated with the severity of the systemic inflammatory response syndrome (SIRS) after infection and is the major cause of death in children with septic shock \[[@CR7], [@CR18]\]. Infections can trigger SIRS by activation of the nuclear factor *kappa*-B (NF-κB), which is the main transcription factor that regulates the expression of genes encoding inflammatory mediators \[[@CR12]\]. These mediators have been implicated in the genesis of sepsis-related myocardial dysfunction \[[@CR18], [@CR26], [@CR27]\], which may contribute to the development of multiple-organ dysfunction syndrome \[[@CR8], [@CR25], [@CR29]\]. In addition, greater NF-κB activation has been observed in adults with septic shock who died \[[@CR1], [@CR4]\]. However, the association between NF-κB activation, sepsis-related myocardial dysfunction, and mortality has not been investigated in children. Improved knowledge on the pathogenesis of organ dysfunction associated with sepsis may lead to novel therapeutic approaches. Thus, the objective of this study was to investigate whether NF-κB activation, as evaluated by gene expression of its inhibitor, I-κBα, and cytokine serum levels, was associated with myocardial dysfunction and mortality in children with septic shock.

Methods {#Sec1}
=======

Ethics Statement {#Sec2}
----------------

This is a prospective, longitudinal, observational cohort study, approved by our Institutional Review Board, Research Ethics Committee of the Hospital das Clinicas, Ribeirao Preto Medical School, University of Sao Paulo (process no. 6060/2005). Written informed consent was obtained from the patients' parents or caregivers.

Patients {#Sec3}
--------

All patients admitted consecutively during an 18-month period to the pediatric intensive care unit (PICU) of Hospital das Clinicas, Ribeirao Preto Medical School, University of Sao Paulo, with a diagnosis of septic shock, according to internationally accepted criteria, were eligible for the study \[[@CR11]\]. Exclusion criteria were as follows: pre-existing congenital heart disease or heart surgery, previous use of cardiotoxic or immunosuppressant drugs, pre-existing coronary artery disease, human immunodeficiency virus infection, newborns, and parental request. All patients were treated according to standardized protocols \[[@CR6]\]. No interventions were made.

Data Collection {#Sec4}
---------------

Clinical and demographic data and outcomes were collected from medical records. PRISM (pediatric risk of mortality) score was calculated within 12 h of PICU admission \[[@CR28]\]. Total inotropic support was estimated by a modified inotropic score calculated as follows: doses of dopamine + dobutamine + milrinone × 10 + epinephrine × 100 + norepinephrine × 100 \[[@CR10]\]. Heart rate, respiratory rate, and systolic blood pressure were adjusted to age and sex. Echocardiography was performed daily starting within 24 h of PICU admission.

Blood Sampling {#Sec5}
--------------

Arterial or venous blood samples were collected into ethylene diamine tetraacetic acid vacuum tubes within the first 24 h of PICU admission. Plasma was separated and stored at −70 °C. The pellet containing blood cells was lysed with a solution of ammonium bicarbonate plus ammonium chloride and centrifuged at 3,000 rpm for 15 min at 4 °C. The supernatant was discarded, and the remaining pellet of RNA, DNA, and protein was resuspended in phosphate-buffered solution and Trizol LS (Invitrogen, Carlsbad, CA), and stored at −70 °C.

Assessment of NF-κB Activation {#Sec6}
------------------------------

Because NF-κB activation induces the production of its own inhibitor (I-κBα), I-κBα gene expression reflects NF-κB activity within the nucleus \[[@CR5]\]. Thus, NF-κB activity was assessed by the relative gene expression of I-κBα by real-time quantitative polymerase chain reaction (7500 Real Time PCR System; Applied Biosystems, Foster City, CA) using a Taqman prime for human I-κBα (reference: Hs_00153283_m1) and GUS-β (Applied Biosystems) as endogenous control. RNA was purified using the chloroform/isopropanol/ethanol method, quantified in a spectrophotometer (Eppendorf BioPhotometer Plus; Eppendorf AG, Hamburg, Germany) and had its quality assessed in 1.2 % agarose gel electrophoresis. Complementary DNA was synthesized with a commercially available kit (High Capacity cDNA Reverse Transcription Kit; Applied Biosystems) according to manufacturer's instructions. I-κBα relative gene expression was calculated by the $\documentclass[12pt]{minimal}
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Because NF-κB is the main transcription factor that regulates the expression of genes encoding cytokines, its activity was also evaluated by plasma concentrations of tumor necrosis factor-*alpha* (TNF-α), interleukin (IL)-6, and IL-10 measured by enzyme-linked immunosorbent assay (ELISA) (DuoSet Elisa Development Systems; R&D Systems, Minneapolis, MN). Values lower than the lower limit of detection were arbitrarily considered as equal to 0.01 pg mL^−1^ for analysis.

Assessment of Myocardial Function {#Sec60}
---------------------------------

Myocardial function was assessed by biochemical and echocardiographic parameters. Patients were divided into two groups according to ejection fraction (EF) \<45 % (group 1 \[moderately or severely decreased LV function\]) or EF ≥45 % (group 2 \[preserved or mildly decreased LV function\]) within 24 h after PICU admission according to American Echocardiographic Society guidelines \[[@CR19]\]. All patients underwent transthoracic bidimensional echocardiography evaluation (Phillips SONOS 5500 \[Phillips Electronics North America, Andover, MA\] or HP Sonos 2500 \[Hewlett-Packard, Palo Alto, CA\]), which was performed daily, starting within 24 h of PICU admission, by one of two echocardiographers with at least 10 years of experience. Left ventricle (LV) status was assessed by ventricle volumes and Teicholz EF. End-systolic and -diastolic LV volumes were estimated by long- and short-axis measurements. Stroke volume was calculated as the difference between end-systolic and -diastolic LV volumes. Cardiac output was estimated by multiplying the calculated stroke volume by the heart rate. Cardiac index (CI) was obtained by dividing cardiac output by body surface area (BSA). Systolic index (SI) was obtained by dividing stroke volume by BSA. End-diastolic LV volume (EDLVV) was also adjusted to BSA.

B-type natriuretic peptide (BNP) was measured in plasma samples using a semiautomated ELISA kit (Triage BNP; Biosite, San Diego, CA), and cardiac troponin I (cTnI) plasma concentration was measured using a semiautomated sandwich immunoassay with fluorescent detection (miniVIDAS; bioMérieux Vitek, Marcy l'Etoile, France).

Statistical Analysis {#Sec7}
--------------------

Results were expressed as median (total range) or counts (percentage). Comparisons between groups were made using Mann--Whitney U test or Student *t* test for continuous variables, according to data distribution, and Fisher's exact test for categorical variables. Correlations between continuous variables were assessed by linear regression models with analysis of residuals. For all tests, logarithmic transformation was applied to IL-6, IL-10, TNF-α, and leukocyte count to normalize data distribution. Because corticosteroid use could be a potential confounder and our sample size would not allow a multivariate analysis, we performed *post hoc* tests comparing inflammatory markers between patients who did and did not receive corticosteroids before enrollment in the study. Statistical software packages Graphpad Prism 5.0 (Graphpad Software, La Jolla, CA) and SPSS 16 (SPSS, Chicago, IL) were used. A *p*-value \<0.05 was considered significant.

Results {#Sec8}
=======

Demographic and Epidemiologic Data {#Sec9}
----------------------------------

Twenty patients with septic shock were enrolled from May 2007 to November 2009. They were studied for a median of 5.5 (range 2--15) days. 6 patients (30 %) had EF \<45 % (group 1), and 14 patients (70 %) had EF ≥45 % (group 2). Demographic and epidemiologic data are listed in Table [1](#Tab1){ref-type="table"}. There were no differences regarding sex, age, body weight, time between first symptoms and PICU admission, or PRISM score between groups. The main diagnoses and the most frequently isolated etiologic agents are listed in Table [2](#Tab2){ref-type="table"}.Table 1Demographic and epidemiologic data of children with septic shock according to LVEF on the first day of ICU admissionDemographic and epidemiologic dataGroup 1 (EF \<45 % \[n = 6\])Group 2 (EF ≥45 % \[n = 14\])*p*Male sex (%)3 (50)8 (57)1.00Age (months)45 (9.7--175)33 (2.3--215)0.56Body weight (kg)17.2 (6.0--40)10.8 (2.2--113)0.71Days from first symptom to PICU admission2 (1--9)4 (1--6)0.38PRISM score12 (6--20)11.5 (0--25)0.90Values shown are number (proportion) or median (range)*EF* ejection fraction (Teicholz), *PICU* pediatric intensive care unit, *PRISM* pediatric risk of mortality, *LVEF* left ventricle ejection fraction Table 2Main diagnoses and etiologic agents of children with septic shock according to LVEFDiagnoses and etiologic agentsGroup 1 (EF = 45 % \[*n* = 6\])Group 2 (EF ≥45 % \[*n* = 14\])Main diagnoses Pneumonia49 Meningoencephalitis11 Toxic shock syndrome12 Infectious diarrhea11 Skin and subcutaneous tissue infections02 Central venous catheter--related infection01Main etiologic agents *Staphylococcus aureus*13 *Pseudomonas aeruginosa*03 *Streptococcus pneumoniae*12 *Acinetobacter baumanii*02 *Candida albicans*02 *Haemophilus influenzae*01 *Enterococcus faecalis*01 *Klebsiella pneumoniae*01 *Enterobacter cloacae*10 *Neisseria meningitidis*01Values shown are counts*EF* ejection fraction (Teicholz), *LVEF* left ventricle ejection fraction

Echocardiographic and Hemodynamic Parameters {#Sec10}
--------------------------------------------

There was no difference between groups in median EDLVV (45 \[range 33--58\] mL.m^−2^ in group 1 vs. 59 \[range 17--93\] mL.m^−2^ in group 2, *p* = 0.34), median CI (2.9 \[range 1.5--4.5\] mL.min^−1^.m^−2^ in group 1 vs. 4.3 \[range 0.8--5.9\] mL.min^−1^.m^−2^ in group 2, *p* = 0.46), or median SI (18.9 \[range 7.4--28.1\] mL.m^−2^ in group 1 vs. 29.8 \[range 8.3--45.1\] mL.m^−2^ in group 2, *p* = 0.15) (Fig. [1](#Fig1){ref-type="fig"}) on the first day of PICU admission. Echocardiograms were performed for a median of 4.5 (range 1--13) days in all patients. Among the patients from group 1, EF increased to \>45 % after a median of 5 (range 3--7) days of PICU admission. Median arterial lactate on the first day after PICU admission was significantly greater in patients from group 1 (3.9 \[range 1.5--28\] mmol.L^−1^ in group 1 vs. 1.5 \[range 0.9--6.3\] mmol.L^−1^ in group 2, *p* = 0.02). However, there were no differences in inotropic score, amount of fluids received, central venous pressure, heart rate, respiratory rate, systolic blood pressure, urine output, or serum creatinine between groups (data not shown).Fig. 1Echocardiographic variables according to EF on first admission day (*n* = 18): Adjusted EDLVV (*p* = 0.34), CI (*p* = 0.46), and SI (*p* = 0.015). The *central line* is the median

Cardiac Markers {#Sec11}
---------------

Within the first 24 h after PICU admission, median cTnI plasma levels were 0.01 (range 0.01--2.6) ng.mL^−1^ in group 1 and 0.01 (range 0.01--4.5) ng.mL^−1^ in group 2 (*p* = 0.82), and median BNP plasma levels were 308 (range 31--597) pg.mL^−1^ in group 1 and 200 (range 5--1,680) pg.mL^−1^ in group 2 (*p* = 0.90).

Inflammatory Markers {#Sec12}
--------------------

Median TNF-α (52.9 \[range 12.6--314\] vs. 8.0 \[range 0.01--76\] pg.mL^−1^, *p* = 0.01) and IL-10 (4.9 \[range 1.9--298\] vs. 4.5 \[range 2.2--9.3\] pg.mL^−1^, *p* = 0.04) plasma levels were significantly greater in patients from group 1 within the first 24 h after PICU admission. However, no differences were observed between groups in IL-6 plasma levels (1,071 \[range 0.7--3,216\] vs. 9.3 \[range 0.5--6,417\] pg.mL^−1^, *p* = 0.15) or I-κBα mRNA expression (4.2 \[range 0.5--11.2\] vs. 2.2 \[range 0.2--15.3\], *p* = 0.56) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Plasma levels of TNF-α (*p* = 0.04), IL-6 (*p* = 0.15), and IL-10 (*p* = 0.04) and I-κBα mRNA relative quantification (*p* = 0.56) according to EF. The *central line* is the median

A significant positive correlation was observed between I-κBα mRNA relative expression and leucocyte count (*r* ^2^ = 0.25, *p* = 0.02) and polymorphonuclear cell count (*r* ^2^ = 0.40, *p* = 0.003) (Fig. [3](#Fig3){ref-type="fig"}). Nevertheless, there was no association between I-κBα mRNA relative expression and IL-6, IL-10, and TNF-α plasma levels or between mononuclear cell and platelet counts. I-κBα mRNA relative expression was also not significantly associated with time between disease onset and admission to the PICU.Fig. 3Correlations between I-κBα mRNA relative quantification and log-transformed plasma levels of IL-6, IL-10, and TNF-α (all nonsignificant) as ell as polymorphonuclear cell count (*r* ^2^ = 0.40, *p* = 0.003)

Post Hoc Analysis: Corticosteroid Use {#Sec13}
-------------------------------------

On the first day of PICU admission, all patients from group 1 (100 %) and 8 patients from group 2 (57 %) had already received hydrocortisone for catecholamine-refractory shock before inclusion in the study. Interestingly, patients who received corticosteroids before entry in the study had greater TNF-α (38.0 \[range 0--314.4\] vs. 8.7 \[range 0--49.8\] pg.mL^−1^, *p* = 0.03), IL-6 (609.0 \[range 0.8--6416.8\] vs. 1.3 \[range 0.5--946.6\] pg.mL^−1^, *p* = 0.01), and IL-10 (15.9 \[range 2.2--297.9\] vs. 4.1 \[range 1.9--5.0\] pg.mL^−1^, *p* = 0.02) plasma levels compared with those who did not receive corticosteroids on the first day after PICU admission. However, no differences in I-κBα mRNA expression were found between them (4.0 \[range 0.1--11.2\] vs. 3.0 \[range 0.6--15.3\], *p* = 0.63).

Outcomes {#Sec14}
--------

Complications occurred more frequently in group 1 (4 \[range 3--7\] vs. 2 \[range 0--5\] complications/patient, *p* = 0.03) (Table [3](#Tab3){ref-type="table"}). The main sites of secondary infections in all patients were lung (*n* = 3), mediastinum (*n* = 1), digestive tract (*n* = 1), and subcutaneous tissue (*n* = 2). Overall mortality was 30 %; it was significantly greater in group 1 (66 vs. 14 %, *p* = 0.03). All deaths were caused by multiple organ failure. Patients who died had greater plasma concentrations of TNF-α (56.1 \[range 10.8--314.4\] vs 8.8 \[0--76.2\] pg.mL^−1^, *p* = 0.01). However, there were no significant differences between survivors and nonsurvivors in plasma concentrations of IL-6 (1196.3 \[range 1.5--3216.2\] vs. 11.4 \[range 0.5--6416.8\] pg.mL^−1^, *p* = 0.07), plasma concentrations of IL-10 (43.0 \[range 2.2 to 297.9\] vs. 4.5 \[range 1.9 to 129.7\] pg.mL^−1^, *p* = 0.29), and mRNA expression of I-κBα (3.0 \[range 0.5--11.2\] vs. 3.4 \[range 0.1--15.3\], *p* = 1).Table 3Complications of children with septic shock according to LVEF on the first day of ICU admissionComplicationGroup 1 (EF \<45 % \[*n* = 6\])Group 2 (EF ≥45 % \[*n* = 14\])Acute kidney failure5 (83)5 (35)ARDS4 (66)4 (28)Steroid use for refractory shock6 (100)8 (57)Seizures2 (33)3 (21)Intracranial hemorrhage or ischemia2 (33)0Intravascular disseminated coagulation6 (100)5 (35)Secondary infection2 (33)5 (35)Other complications^a^1 (16)3 (21)Death4 (66)2 (14)Values shown are number (percentage)*EF* ejection fraction (Teicholz), *ARDS* acute respiratory distress syndrome^a^Lung abscess, diabetes insipidus, pulmonary hypertension, and necrosis of extremities

Discussion {#Sec15}
==========

We have shown that children with moderate-to-severe myocardial dysfunction (EF \<45 %) associated with septic shock had greater plasma levels of TNF-α and IL-10, more complications. and greater mortality compared with those with preserved or mildly decreased LV function (EF ≥45 %). Moreover, patients who died had greater plasma concentrations of TNF-α. However, there was no significant difference in I-κBα mRNA expression between patients with and without moderate-to-severe myocardial dysfunction or between survivors and nonsurvivors. In addition, plasma levels of cytokines did not correlate with I-κBα mRNA expression.

Although the study groups had different EF, there were no significant differences regarding other echocardiographic parameters of myocardial performance or cardiac biochemical markers, such as cTnI and BNP plasma levels, probably because the patients were already on inotropic support at the time of assessment. Nevertheless, arterial lactate levels were significantly greater in patients from group 1. In accordance with adult data \[[@CR24]\], myocardial dysfunction was fully reversible in survivors with normalization of EF after 3--7 days of initiation of treatment.

Conflicting results have been reported regarding the serum cytokine profile in patients with septic shock. It has been showed that TNF-α and IL-1β were responsible for the depression of myocardial cell contractility in vitro induced by human septic shock serum \[[@CR18]\]. In contrast, serum from septic shock adults that induced a decrease of cardiomyocyte contractility in vitro had high levels of IL-6, IL-8 and IL-10; however, the concentrations of TNF-α and IL-1β were not increased \[[@CR16]\]. IL-6 isolated from serum obtained from children with meningococcal septicemia impaired in vitro myocardial contractility \[[@CR26]\]. TNF-α added to IL-6 had negative inotropic activity in vitro after prolonged exposure (\>48 h) \[[@CR27]\]. Our data add to the evidence that TNF-α and IL-10 are involved in myocardial contractile dysfunction associated with septic shock. Moreover, we observed greater levels of TNF-α, IL-6, and IL-10 in patients with catecholamine-refractory shock, and there was an association between TNF-α levels and mortality. In children with septic shock, serum levels of TNF and IL-10 measured at admission to the PICU were related to the severity of organ failure and mortality \[[@CR13]\]. Taken together, these findings suggest that inflammation is associated with disease severity and outcome of children with septic shock. Interestingly, experimental studies have showed that in addition to the systemic release of cytokines, cardiomyocytes can also generate cytokines locally in the heart in response to Gram-positive sepsis and lipopolysaccharide administration, which could aggravate sepsis-induced myocardial dysfunction \[[@CR14], [@CR17], [@CR20]\]. However, evaluation of cytokine production by cardiomyocytes is not clinically feasible.

Increased NF-κB activation, assessed by electrophoretic mobility shift assay (EMSA), has been reported in adults with septic shock who died \[[@CR1], [@CR4]\]. In children with sepsis, flow cytometric analysis showed a greater percentage of monocytes/macrophages and polymorphonuclear cells exhibiting NF-κB activity compared with controls. Moreover, a positive correlation has been observed between the percentage of cells exhibiting NF-κB activity and serum levels of IL-6 and IL-10 \[[@CR15]\]. In contrast, NF-κB activity, as evaluated by gene expression of its inhibitor, I-κBα, was not associated with myocardial dysfunction or mortality in our study. In theory, I-κBα mRNA quantification would be a more accurate marker of the transcriptional strength of NF-κB \[[@CR5]\]. EMSA, which visualizes the binding of NF-κB to synthetic oligonucleotides, does not necessarily reflect the transcriptional power of NF-κB because it can be modified after NF-κB DNA binding by phosphorylation or interaction with cofactors \[[@CR5]\]. However, several substances can influence I-κBα mRNA levels, such as corticosteroids, which lead to increased transcription of the gene for I-κBα \[[@CR2]\]. Because most patients (14 of 20) had received corticosteroids before entry in the study, this may have altered I-κBα gene expression.

Although studies on anti-inflammatory agents for sepsis have shown protective effects in animal models \[[@CR3], [@CR9], [@CR31], [@CR32]\], clinical trials have found inconsistent results \[[@CR30]\]. Nevertheless, the efficacy of anti-inflammatory agents in sepsis appears to be related to sepsis-associated risk of death \[[@CR23]\]. Clinical trials have been performed with the use of a polyclonal antibody against TNF, and preliminary results suggest that it may be beneficial in patients with severe sepsis and shock or evolving organ failure \[[@CR22], [@CR23]\]. This could be a therapeutic option for children with severe myocardial dysfunction at high risk of death. Further studies are needed to elucidate this option.

As a limitation, the correlation between I-κBα mRNA expression and NF-κB protein could not be studied. Nevertheless, quantifying the NF-κB protein would not have provided information on the degree of NF-κB activity within the nucleus. In addition, our limited sample size does not allow us to draw any definite conclusion, and larger studies are urgently needed.

Conclusion {#Sec16}
==========

In conclusion, TNF-α and IL-10 are involved in myocardial dysfunction and TNF-α is associated with mortality in children with septic shock. Anti-inflammatory agents, such as TNF inhibitors, may be a therapeutic option for these patients.
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